Matthew B. Rivara
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Matthew B. Rivara has a total of 130 co-authors. Here are the top co-authors by number of shared publications:
Rajnish Mehrotra
Division of Nephrology, Department of Medicine, University of Washington, Seattle, Washington, USA
10 shared publications- Rajnish Mehrotra
University of Washington
8 shared publications Jonathan Himmelfarb
Kidney Research Institute, University of Washington, Seattle, Washington
7 shared publications- Kamyar Kalantar-Zadeh
Division of Nephrology and Hypertension and Transplantation, Harbor-UCLA Medical Center and the Lundquist Institute, Torrance, California
6 shared publications Elani Streja
Harold Simmons Center for Kidney Disease Research and Epidemiology, Division of Nephrology and Hypertension, University of California Irvine Medical Center, Irvine, California; and
5 shared publications- Jonathan Himmelfarb
Icahn School of Medicine at Mount Sinai, New York, New York
4 shared publications
Latest Publications
- 27 October 2026
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
System Innovations for Personalized Peritoneal Dialysis Care
Was not provided for this article.
- 27 October 2026
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
System Innovations for Personalized Peritoneal Dialysis Care
Was not provided for this article.
- 9 July 2026
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 37  (9) , 2065-2073
Assessment of Medicare Advantage Stars Measures
The Centers for Medicare & Medicaid Services uses the Star quality program to evaluate Medicare Advantage (Medicare Part C) care quality. Since the 21st Century Cures Act, ESRD enrollment within Medicare has shifted from e.g ., customer service). The American Society of Nephrology committee evaluated 25 (of 45) Star quality measures that were directly related to clinical outcomes. The committee assessment identified 13 high-validity Star measures that monitored care related to diabetes, hypertension, and care transitions, as well as 12 medium-validity measures that evaluated preventive care and other chronic care areas. The appropriateness and clinical evidence base of Star measures were generally strong but weaker in patients with kidney failure. The committee noted concerns with ten Stars measures that may exclude patients with kidney failure. Only one measure captured guideline-directed kidney care (albuminuria screening in patients with diabetes). No Stars measures captured other guideline-directed recommendations, such as CKD screening and risk stratification, nephrology referral, use of kidney pharmacotherapies, CKD education, or preemptive kidney transplantation referral. The Medicare 2026 Part C and D Stars measures represent a missed opportunity to align care measures and guideline-directed kidney care to improve outcomes, reduce costs, and advance high-value care for the millions of Americans living with kidney disease.
- 9 July 2026
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 37  (9) , 2065-2073
Assessment of Medicare Advantage Stars Measures
The Centers for Medicare & Medicaid Services uses the Star quality program to evaluate Medicare Advantage (Medicare Part C) care quality. Since the 21st Century Cures Act, ESRD enrollment within Medicare has shifted from e.g ., customer service). The American Society of Nephrology committee evaluated 25 (of 45) Star quality measures that were directly related to clinical outcomes. The committee assessment identified 13 high-validity Star measures that monitored care related to diabetes, hypertension, and care transitions, as well as 12 medium-validity measures that evaluated preventive care and other chronic care areas. The appropriateness and clinical evidence base of Star measures were generally strong but weaker in patients with kidney failure. The committee noted concerns with ten Stars measures that may exclude patients with kidney failure. Only one measure captured guideline-directed kidney care (albuminuria screening in patients with diabetes). No Stars measures captured other guideline-directed recommendations, such as CKD screening and risk stratification, nephrology referral, use of kidney pharmacotherapies, CKD education, or preemptive kidney transplantation referral. The Medicare 2026 Part C and D Stars measures represent a missed opportunity to align care measures and guideline-directed kidney care to improve outcomes, reduce costs, and advance high-value care for the millions of Americans living with kidney disease.
- 1 July 2026
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 21  (9) , 1584-1592
Prospective Cohort Study Evaluating Impact of Hemodialysis on Glycemia
Background: Hemodialysis affects glycemia in a manner that remains incompletely defined. Methods: In a prospective cohort study, 342 participants on maintenance hemodialysis wore a Dexcom G6 Pro continuous glucose monitor (CGM) for 10 days while dialyzing with standardized 100 mg/dL glucose dialysate. We examined glycemia relative to dialysis timing and tested associations of glycemia patterns with clinical characteristics and markers of overall glycemic control. Glucoregulatory hormones were measured pre- and post-dialysis in a subset of 20 participants. Results: Overall, CGM captured 1,001 hemodialysis sessions. Among participants with treated diabetes (n=143), untreated diabetes (n=78), and without diabetes (n=121), pre-dialysis glucose averaged 212 ± 84 mg/dL, 167 ± 65 mg/dL, and 120 ± 28 mg/dL, respectively. During dialysis, glucose declined by 53 ± 79 mg/dL, 29 ± 55 mg/dL, and 7 ± 32 mg/dL, respectively. Post-dialysis, glucose rebounded by 115 ± 70 mg/dL (to mean peak 265 ± 84 mg/dL), 95 ± 60 mg/dL (227 ± 71 mg/dL) and 61 ± 35 mg/dL (168 ± 37 mg/dL), respectively, with mean time to peak occurring later in treated (172 minutes post-dialysis) and untreated (169 min) diabetes compared with no diabetes (140 min). Post-dialytic rebound glycemia correlated with hemoglobin A1c and mean CGM glucose over the full observation period. Hypoglycemic events <70 mg/dL were uncommon (N=259); hypoglycemic event rates were significantly higher in the post-dialysis period compared with time-matched periods on non-dialysis days. There were no significant differences in hypoglycemic event rates pre- versus post-dialysis on dialysis days. In the substudy, most glucoregulatory peptides declined significantly (p<0.001) during dialysis including insulin (median change: -38%), glucagon (-43%), and glucagon-like peptide-1 (-38%). Conclusions: Hemodialysis induces intradialytic glucose declines and post-dialytic rebound that link to overall glycemic control, highlighting dialysis as a physiologic stressor on glucose homeostasis.
- 1 July 2026
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 21  (9) , 1584-1592
Prospective Cohort Study Evaluating Impact of Hemodialysis on Glycemia
Background: Hemodialysis affects glycemia in a manner that remains incompletely defined. Methods: In a prospective cohort study, 342 participants on maintenance hemodialysis wore a Dexcom G6 Pro continuous glucose monitor (CGM) for 10 days while dialyzing with standardized 100 mg/dL glucose dialysate. We examined glycemia relative to dialysis timing and tested associations of glycemia patterns with clinical characteristics and markers of overall glycemic control. Glucoregulatory hormones were measured pre- and post-dialysis in a subset of 20 participants. Results: Overall, CGM captured 1,001 hemodialysis sessions. Among participants with treated diabetes (n=143), untreated diabetes (n=78), and without diabetes (n=121), pre-dialysis glucose averaged 212 ± 84 mg/dL, 167 ± 65 mg/dL, and 120 ± 28 mg/dL, respectively. During dialysis, glucose declined by 53 ± 79 mg/dL, 29 ± 55 mg/dL, and 7 ± 32 mg/dL, respectively. Post-dialysis, glucose rebounded by 115 ± 70 mg/dL (to mean peak 265 ± 84 mg/dL), 95 ± 60 mg/dL (227 ± 71 mg/dL) and 61 ± 35 mg/dL (168 ± 37 mg/dL), respectively, with mean time to peak occurring later in treated (172 minutes post-dialysis) and untreated (169 min) diabetes compared with no diabetes (140 min). Post-dialytic rebound glycemia correlated with hemoglobin A1c and mean CGM glucose over the full observation period. Hypoglycemic events <70 mg/dL were uncommon (N=259); hypoglycemic event rates were significantly higher in the post-dialysis period compared with time-matched periods on non-dialysis days. There were no significant differences in hypoglycemic event rates pre- versus post-dialysis on dialysis days. In the substudy, most glucoregulatory peptides declined significantly (p<0.001) during dialysis including insulin (median change: -38%), glucagon (-43%), and glucagon-like peptide-1 (-38%). Conclusions: Hemodialysis induces intradialytic glucose declines and post-dialytic rebound that link to overall glycemic control, highlighting dialysis as a physiologic stressor on glucose homeostasis.
- 27 October 2025
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 21  (1) , 141-143
A Qualitative Study of Nephrologists' Perceptions of Management of Hypertension in Hemodialysis Patients
- 27 October 2025
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 21  (1) , 141-143
A Qualitative Study of Nephrologists' Perceptions of Management of Hypertension in Hemodialysis Patients
- 10 October 2025
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 21  (5) , 907-909
How I Treat Nocturnal Home Hemodialysis—An Underprescribed but Essential Home Dialysis Modality in the United States
- 10 October 2025
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 21  (5) , 907-909
How I Treat Nocturnal Home Hemodialysis—An Underprescribed but Essential Home Dialysis Modality in the United States
- 9 September 2025
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 21  (3) , 529-532
International Society for Peritoneal Dialysis Journal Club
- 9 September 2025
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 21  (3) , 529-532
International Society for Peritoneal Dialysis Journal Club
- 21 March 2025
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 36  (9) , 1798-1810
Glycemia Assessed by Continuous Glucose Monitoring among People Treated with Maintenance Dialysis
Key Points: In maintenance dialysis, continuous glucose monitoring frequently identified both hyperglycemia and hypoglycemia that may not be clinically evident. Patients with treated diabetes rarely met contemporary continuous glucose monitoring–based treatment targets. Background: Kidney failure and its treatments disrupt glucose homeostasis in ways that may promote both hyperglycemia and hypoglycemia. Continuous glucose monitoring (CGM) delineates detailed glycemic profiles, but published studies in kidney failure are limited to small, select groups. We aimed to characterize the spectrum of glycemia and its determinants in a large, diverse maintenance dialysis population. Methods: We conducted a prospective community-based cohort study of people treated with maintenance dialysis. Each participant wore a Dexcom G6 Pro CGM for approximately 10 days. Outcomes ascertained by CGM included mean blood glucose, time in range (TIR, 70–180 mg/dl), and hypoglycemia events (sustained P < 0.001). Among participants with untreated diabetes, the mean blood glucose was 162 mg/dl, mean TIR 71%, and only 64% of participants attained TIR ≥70%, while mean hemoglobin A1c (HbA1c) was 5.7%. Among participants with treated diabetes, the mean blood glucose was 214 mg/dl, the mean TIR was 43%, and only 22% of participants attained TIR ≥70%, while the mean HbA1c was 7.0%. In total, 714 unique sustained hypoglycemia events were observed, with highest rates for participants without diabetes. In addition to diabetes and dialysis modality, age, dialysis vintage, insulin use, HbA1c, and serum albumin were significantly associated with mean blood glucose, hypoglycemia, or both. Conclusions: In maintenance dialysis, CGM frequently identified both hyperglycemia and hypoglycemia that may not be clinically evident. In particular, hyperglycemia was common with PD, patients with untreated diabetes maintained a diabetic glycemic profile, and patients with treated diabetes rarely met contemporary CGM-based treatment targets.
- 21 March 2025
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 36  (9) , 1798-1810
Glycemia Assessed by Continuous Glucose Monitoring among People Treated with Maintenance Dialysis
Key Points: In maintenance dialysis, continuous glucose monitoring frequently identified both hyperglycemia and hypoglycemia that may not be clinically evident. Patients with treated diabetes rarely met contemporary continuous glucose monitoring–based treatment targets. Background: Kidney failure and its treatments disrupt glucose homeostasis in ways that may promote both hyperglycemia and hypoglycemia. Continuous glucose monitoring (CGM) delineates detailed glycemic profiles, but published studies in kidney failure are limited to small, select groups. We aimed to characterize the spectrum of glycemia and its determinants in a large, diverse maintenance dialysis population. Methods: We conducted a prospective community-based cohort study of people treated with maintenance dialysis. Each participant wore a Dexcom G6 Pro CGM for approximately 10 days. Outcomes ascertained by CGM included mean blood glucose, time in range (TIR, 70–180 mg/dl), and hypoglycemia events (sustained P < 0.001). Among participants with untreated diabetes, the mean blood glucose was 162 mg/dl, mean TIR 71%, and only 64% of participants attained TIR ≥70%, while mean hemoglobin A1c (HbA1c) was 5.7%. Among participants with treated diabetes, the mean blood glucose was 214 mg/dl, the mean TIR was 43%, and only 22% of participants attained TIR ≥70%, while the mean HbA1c was 7.0%. In total, 714 unique sustained hypoglycemia events were observed, with highest rates for participants without diabetes. In addition to diabetes and dialysis modality, age, dialysis vintage, insulin use, HbA1c, and serum albumin were significantly associated with mean blood glucose, hypoglycemia, or both. Conclusions: In maintenance dialysis, CGM frequently identified both hyperglycemia and hypoglycemia that may not be clinically evident. In particular, hyperglycemia was common with PD, patients with untreated diabetes maintained a diabetic glycemic profile, and patients with treated diabetes rarely met contemporary CGM-based treatment targets.
- 14 February 2025
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 36  (5) , 976-980
Optimizing Quality Care within a Bundled Framework
- 14 February 2025
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 36  (5) , 976-980
Optimizing Quality Care within a Bundled Framework
- 17 May 2024
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 19  (6) , 688-690
Prescribing Peritoneal Dialysis in the United States
- 17 May 2024
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 19  (6) , 688-690
Prescribing Peritoneal Dialysis in the United States
- 23 January 2024
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 19  (5) , 602-609
Evaluation and Measurement Properties of a Patient-Reported Experience Measure for Home Dialysis
Background: No previously validated patient-reported experience measures exist for use among patients undergoing home dialysis. We tested the Home Dialysis Care Experience survey, a newly developed 26-item experience measure, among patients from 30 dialysis facilities in the United States. Methods: Using mail and telephone survey modalities, we approached 1372 patients treated with peritoneal dialysis or home hemodialysis for participation. Using the results from completed surveys, we evaluated item calibration by assessing item floor and ceiling effects. We tested three sets of composite scores and used factor analysis to assess model fit for each. We evaluated associations of composite scores with global ratings and separately with patient and dialysis facility characteristics. Finally, we measured test–retest reliability in patients who completed the survey at two separate time points. Results: Overall, 495 eligible patients completed at least one survey (response rate 36%). Of these, 49 completed the survey in Spanish and 61 completed a second survey within 30 days. We did not detect significant floor or ceiling effects, except for one item that demonstrated >90% responses at the top response option. Analyses supported one 12-item composite scale with high internal consistency reliability: Quality of Home Dialysis Care and Operations (Cronbach alpha=0.85). This scale strongly correlated with overall staff rating ( r =0.73) and overall center rating ( r =0.70). Patient demographic and dialysis facility characteristics were not consistently associated with composite scale scores or overall staff or center ratings. Intraclass correlation coefficients in the test–retest population were 0.74 for the Quality scale, 0.88 for overall staff rating, and 0.90 for overall center rating. Conclusions: The Home Dialysis Care Experience survey is a 26-item measure that includes one composite scale and two global rating scores and is an informative tool to evaluate patient experience of care for home dialysis.
- 23 January 2024
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 19  (5) , 602-609
Evaluation and Measurement Properties of a Patient-Reported Experience Measure for Home Dialysis
Background: No previously validated patient-reported experience measures exist for use among patients undergoing home dialysis. We tested the Home Dialysis Care Experience survey, a newly developed 26-item experience measure, among patients from 30 dialysis facilities in the United States. Methods: Using mail and telephone survey modalities, we approached 1372 patients treated with peritoneal dialysis or home hemodialysis for participation. Using the results from completed surveys, we evaluated item calibration by assessing item floor and ceiling effects. We tested three sets of composite scores and used factor analysis to assess model fit for each. We evaluated associations of composite scores with global ratings and separately with patient and dialysis facility characteristics. Finally, we measured test–retest reliability in patients who completed the survey at two separate time points. Results: Overall, 495 eligible patients completed at least one survey (response rate 36%). Of these, 49 completed the survey in Spanish and 61 completed a second survey within 30 days. We did not detect significant floor or ceiling effects, except for one item that demonstrated >90% responses at the top response option. Analyses supported one 12-item composite scale with high internal consistency reliability: Quality of Home Dialysis Care and Operations (Cronbach alpha=0.85). This scale strongly correlated with overall staff rating ( r =0.73) and overall center rating ( r =0.70). Patient demographic and dialysis facility characteristics were not consistently associated with composite scale scores or overall staff or center ratings. Intraclass correlation coefficients in the test–retest population were 0.74 for the Quality scale, 0.88 for overall staff rating, and 0.90 for overall center rating. Conclusions: The Home Dialysis Care Experience survey is a 26-item measure that includes one composite scale and two global rating scores and is an informative tool to evaluate patient experience of care for home dialysis.